logo
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo13-06-2025
LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the 'Company'), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on June 2, 2025, of (i) 160,000 restricted stock units ('RSUs') of the Company's Class A common stock ('Common Stock') and (ii) non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the 'Options') as a material inducement to employment to a new employee. All such equity awards were made under the Company's Inducement Plan, as amended (the 'Inducement Plan') and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.
The Options have an exercise price of $3.45 per share, which is equal to the closing price of Common Stock on their grant date. Twenty-five percent (25%) of Options will vest and become exercisable on the first anniversary of their grant date, and 1/48th of Options will vest and become exercisable each month thereafter, in each case, subject to such employee's continued employment on each vesting date.
The RSUs will vest annually over a three-year period, with one-third of the RSUs vesting on each anniversary of their grant date, subject to such employee's continued employment on each vesting date.
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ('MQC') testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.CONTACT: Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.comSign in to access your portfolio
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Piper Sandler: Tesla (TSLA) Jury Ruling Is No Reason to Panic
Piper Sandler: Tesla (TSLA) Jury Ruling Is No Reason to Panic

Yahoo

time31 minutes ago

  • Yahoo

Piper Sandler: Tesla (TSLA) Jury Ruling Is No Reason to Panic

Tesla, Inc. (NASDAQ:TSLA) is one of the . On August 4, Piper Sandler analyst Alexander Potter reiterated an "Overweight" rating on the stock with a $400.00 price target. The firm said investors shouldn't be over-reacting to headlines surrounding Tesla's recent Autopilot-related jury verdict in Florida. It believes the case is less significant than it seems. 'In our years covering TSLA, we've learned to ignore headlines related to Autopilot liability. But the robotaxi roll-out has breathed new life into this topic, and we feel compelled to comment on recent media intrigue. On Friday, when a jury in Florida found Tesla partially liable for a 2019 crash, headlines began proliferating, referring to a 'stunning rebuke', a 'massive blow', and a $243M obligation. In our view, these headlines paint an unrealistically negative picture. In short, we don't think shareholders should be losing sleep over this.' Pixabay / Public Domain Tesla, Inc. (NASDAQ:TSLA) is an automotive and clean energy company that leverages advanced artificial intelligence in its autonomous driving technology and robotics initiatives. While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Datadog (DDOG) Up 54%—Analyst Still Bullish Heading Into Q2 Results
Datadog (DDOG) Up 54%—Analyst Still Bullish Heading Into Q2 Results

Yahoo

time31 minutes ago

  • Yahoo

Datadog (DDOG) Up 54%—Analyst Still Bullish Heading Into Q2 Results

Datadog, Inc. (NASDAQ:) is one of the . On August 4, UBS analyst Karl Keirstead reiterated a 'Buy' rating on the stock with a $165.00 price target. The company is expected to report earnings for the fiscal quarter ending June 2025 on 08/07/2025 before market open. The firm believes that Datadog is heading into earnings with strong cloud tailwinds overblown concerns regarding OpenAI. However, the recent 54% rally since early April makes the stock less compelling. 'Ahead of Datadog's 2Q25 print on Thursday morning, we review the key debates, including overall observability software spending trends, the health of the OpenAI-Datadog relationship and the impact of the (slightly) disappointing AWS results." Here's why the firm is still leaning positive to Datadog: "While the 54% rally in the stock since early-April (the shares are back to 12x/42x on CY26E revs/FCF) makes the set-up less compelling, we still lean positive given Datadog's correlation to a very healthy cloud infra market as well as our view that the Street is over-indexing too negative on the OpenAI risk.' Datadog, Inc. (NASDAQ:DDOG) offers a cloud-based SaaS platform for monitoring and analytics, specializing in cloud computing and AI-powered cybersecurity products. While we acknowledge the potential of DDOG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Sign in to access your portfolio

Microsoft (MSFT) Stock Upgraded—Here's Why Azure Is the Game-Changer
Microsoft (MSFT) Stock Upgraded—Here's Why Azure Is the Game-Changer

Yahoo

time31 minutes ago

  • Yahoo

Microsoft (MSFT) Stock Upgraded—Here's Why Azure Is the Game-Changer

Microsoft Corporation (NASDAQ:MSFT) is one of the AI Stocks Analysts Are Watching Closely. On July 31, KeyBanc analyst Jackson Ader upgraded the stock from Sector Weight to 'Overweight' with a price target of $630.00. Microsoft's Azure cloud segment has been accelerating, growing 39% in constant currency by the end of the fiscal year. Azure has been outperforming the firm's expectations over the recent quarters due to increasing core Cloud migrations among large enterprise customers. Back in April, capital expenditure concerns and depreciation expenses impact on gross margins had led the firm to downgrade the stock. Microsoft has since laid off 1,000 employees, and there has been no mention of macroeconomic headwinds that analysts had previously feared. 'The reasons for our April downgrade were centered around worries that capex and depreciation expense would hamper gross margins and again inflame the debate on AI return-on-investment, coupled with a skepticism that the Company would have the willingness or ability to continue to cut headcount enough to defend its margins. Plus there were macro concerns picked up in our survey work during the spring that we felt would impact Microsoft more than the rest of the sector. Azure growth accelerated eight full percentage points in constant currency over the second half, from 31% in January to 35% in March to 39% exiting the year. The last two quarters have rendered the debates all but irrelevant for the time being." An investor intently focused on the stock exchange monitor. "The Azure segment produced roughly $500M and $700M of upside to guidance in the last two quarters, respectively, the equivalent of finding a in your couch cushions. Upside like this is why we do not expect the costs of supporting the Azure business to be debated much for the remainder of the year. Further, there was no material mention of macro headwinds on the call and, since the time of our fears over needing to cut operating expenses in order to defend margins, Microsoft has laid off over 10,000 employees.' Microsoft Corporation (NASDAQ:MSFT) provides AI-powered cloud, productivity, and business solutions, focusing on efficiency, security, and AI advancements. While we acknowledge the potential of MSFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store